A plasma metabolomic signature discloses human breast cancer.

Autor:	Jové M; Department of Experimental Medicine, University of Lleida-Institute for Research in Biomedicine of Lleida (UdL-IRBLleida), Lleida, Spain., Collado R; Department of Oncology, Medical Oncology Unit, Hospital San Pedro de Alcántara, Cáceres, Official Postgraduate Programme in Nutrition and Food Technology, University of Granada, Spain., Quiles JL; Institute of Nutrition and Food Technology 'José Mataix', Biomedical Research Center, Department of Physiology, University of Granada, Granada, Spain., Ramírez-Tortosa MC; Institute of Nutrition and Food Technology 'José Mataix', Biomedical Research Center, Department of Biochemistry and Molecular Biology II, University of Granada, Granada, Spain., Sol J; Department of Experimental Medicine, University of Lleida-Institute for Research in Biomedicine of Lleida (UdL-IRBLleida), Lleida, Spain., Ruiz-Sanjuan M; Department of Medical Oncology, Hospital of Jaén, Jaén, Spain., Fernandez M; Department of Medical Oncology, Hospital of Jaén, Jaén, Spain., de la Torre Cabrera C; Department of Medical Oncology, Hospital of Jaén, Jaén, Spain., Ramírez-Tortosa C; Department of Pathological Anatomy, Hospital of Jaén, Jaén, Spain.; GENYO, Centre for Genomics and Oncological Research (Pfizer / University of Granada / Andalusian Regional Government), PTS Granada, Granada, Spain., Granados-Principal S; Department of Medical Oncology, Hospital of Jaén, Jaén, Spain., Sánchez-Rovira P; Department of Medical Oncology, Hospital of Jaén, Jaén, Spain., Pamplona R; Department of Experimental Medicine, University of Lleida-Institute for Research in Biomedicine of Lleida (UdL-IRBLleida), Lleida, Spain.
Jazyk:	angličtina
Zdroj:	Oncotarget [Oncotarget] 2017 Mar 21; Vol. 8 (12), pp. 19522-19533.
DOI:	10.18632/oncotarget.14521
Abstrakt:	Purpose: Metabolomics is the comprehensive global study of metabolites in biological samples. In this retrospective pilot study we explored whether serum metabolomic profile can discriminate the presence of human breast cancer irrespective of the cancer subtype. Methods: Plasma samples were analyzed from healthy women (n = 20) and patients with breast cancer after diagnosis (n = 91) using a liquid chromatography-mass spectrometry platform. Multivariate statistics and a Random Forest (RF) classifier were used to create a metabolomics panel for the diagnosis of human breast cancer. Results: Metabolomics correctly distinguished between breast cancer patients and healthy control subjects. In the RF supervised class prediction analysis comparing breast cancer and healthy control groups, RF accurately classified 100% both samples of the breast cancer patients and healthy controls. So, the class error for both group in and the out-of-bag error were 0. We also found 1269 metabolites with different concentration in plasma from healthy controls and cancer patients; and basing on exact mass, retention time and isotopic distribution we identified 35 metabolites. These metabolites mostly support cell growth by providing energy and building stones for the synthesis of essential biomolecules, and function as signal transduction molecules. The collective results of RF, significance testing, and false discovery rate analysis identified several metabolites that were strongly associated with breast cancer. Conclusions: In breast cancer a metabolomics signature of cancer exists and can be detected in patient plasma irrespectively of the breast cancer type.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu